Pfizer Hit With Securities Suit Over Bextra Marketing

Law360, New York (May 11, 2010, 7:19 PM EDT) -- Pfizer Inc. was hit Tuesday with another securities fraud class action over its anti-inflammatory drug Bextra, this time being accused of failing to tell investors it was illegally promoting off-label uses for Bextra and three other drugs and offering kickbacks to doctors to promote the medications.

The lawsuit was filed in the U.S. District Court for the Southern District of New York, according to a statement from Robbins Geller Rudman & Dowd LLP, the firm representing the lead plaintiff.

The complaint alleges Pfizer's directors and officers...
To view the full article, register now.